| Obesity |
1 |
1 |
| Weight Management |
0 |
0.84 |
| Bariatric Surgery |
0 |
0.78 |
| Weight Loss |
0 |
0.75 |
| GLP-1 Receptor Agonist |
0 |
0.45 |
| Weight Gain |
0 |
0.37 |
| Receptors |
0 |
0.28 |
| Type 2 Diabetes Mellitus |
0 |
0.17 |
| Diet |
0 |
0.14 |
| Exercise |
0 |
0.14 |
| Heart |
0 |
0.14 |
| Mental Illness |
0 |
0.95 |
| Hypertension |
0 |
0.13 |
| Heart Failure (HF) |
0 |
0.12 |
| Atypical Antipsychotics |
0 |
0.1 |
| Antipsychotics |
0 |
0.09 |
| Maryland |
0 |
0.09 |
| Massachusetts |
0 |
0.09 |
| Stimulants |
0 |
0.09 |
| COVID-19 |
0 |
0.07 |
| Cerebrovascular Accident |
0 |
0.06 |
| Revenue and Practice Management |
0 |
0.75 |
| Adverse Effects |
0 |
0.05 |
| Brain |
0 |
0.05 |
| Dorsum |
0 |
0.05 |
| Fellowship |
0 |
0.05 |
| Food and Drug Administration (FDA) |
0 |
0.6 |
| Hospital |
0 |
0.05 |
| Insurance |
0 |
0.05 |
| Jobs |
0 |
0.05 |
| Medicaid |
0 |
0.05 |
| Medicare |
0 |
0.05 |
| Metabolic Syndrome |
0 |
0.05 |
| Metabolism |
0 |
0.05 |
| Nausea |
0 |
0.05 |
| Pandemic |
0 |
0.05 |
| Patient Safety |
0 |
0.05 |
| Peer Review |
0 |
0.05 |
| Pennsylvania |
0 |
0.05 |
| Primary Care |
0 |
0.05 |
| Psychotropic Drugs |
0 |
0.05 |
| Pulmonary Arterial Hypertension |
0 |
0.05 |
| Pulmonary Hypertension |
0 |
0.05 |
| Retirement |
0 |
0.05 |
| Sleep |
0 |
0.05 |
| Statistics |
0 |
0.05 |
| Surgery |
0 |
0.05 |
| Tissue |
0 |
0.05 |
| Addiction |
0 |
0.03 |
| Schizophrenia |
0 |
0.03 |